SIU 2017: Recirculative Neoadjuvant Chemohyperthermia in NMIBC Patients

Lisbon, Portugal (  The authors presented a study where they reviewed the safety and efficacy of neoadjuvant Hyperthermic Intra-VEsical Chemotherapy (“HIVEC"), delivered with the COMBAT system in a group of patients with intermediate or high risk non-muscle invasive bladder cancer (NMIBC).

The protocol entailed a total of 8 weekly instillations of 80 mg of Mitomycin-c (MMC) diluted in 50ml of distilled water, recirculated through the bladder during one hour at a 43°C (+0.5°C). A complete TURBT was then performed and pathologic findings were analyzed. A total of 37 patients were treated in the Monforte Comarcal Hospital (Spain) between December 2010 and December 2016. Tolerance data were recorded and quality of life FACT-BI and IPSS questionnaires were completed. Follow up of patients varied from 6 to 78 months to detect any residual disease or long term complications.

The results showed that 96.3% (285 of 296) of the scheduled “HIVEC" neo adjuvant treatments were completed. The most frequent adverse events were only mild (Grade 1). Complete response (confirmed pathology) rate was 62.1% (n=23). Partial response (reduction of tumour load >50%) was 32.4% (n=12), and non-responder was 5.4% (n=2). The cumulative incidence of recurrence at 5 years was 26.1% (95%CI: 4.1% to 45.3%).

In conclusion, Combat-BRS has a favorable side effect profile. Neoadjuvant “HIVEC" treatment seems to be effective against NMIBC. It achieves the complete elimination of the tumor in two thirds of the treated patients and obtained a low number of relapses in up to 5 years of follow up. Additional randomized clinical trials are needed to clarify the use of this modality the clinical practice.

Presented by: Sousa-Escandón A.
Affiliation: Comarcal Hospital of Monforte, Monforte de Lemos, Spain

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.